FBLG vs. CRDL, LITS, EQ, QNCX, ASRT, ENTX, PRLD, IZTC, CNTB, and VXRT
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Cardiol Therapeutics (CRDL), Lite Strategy (LITS), Equillium (EQ), Quince Therapeutics (QNCX), Assertio (ASRT), Entera Bio (ENTX), Prelude Therapeutics (PRLD), Invizyne Technologies (IZTC), Connect Biopharma (CNTB), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry.
FibroBiologics vs. Its Competitors
FibroBiologics (NASDAQ:FBLG) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Cardiol Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.
FibroBiologics currently has a consensus price target of $12.67, indicating a potential upside of 2,789.95%. Cardiol Therapeutics has a consensus price target of $8.00, indicating a potential upside of 661.90%. Given FibroBiologics' higher possible upside, analysts plainly believe FibroBiologics is more favorable than Cardiol Therapeutics.
Cardiol Therapeutics' return on equity of -232.26% beat FibroBiologics' return on equity.
12.5% of Cardiol Therapeutics shares are held by institutional investors. 20.8% of FibroBiologics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
FibroBiologics has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
In the previous week, Cardiol Therapeutics had 1 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 3 mentions for FibroBiologics. Cardiol Therapeutics' average media sentiment score of 0.81 beat FibroBiologics' score of 0.63 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.
Summary
Cardiol Therapeutics beats FibroBiologics on 8 of the 14 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
This page (NASDAQ:FBLG) was last updated on 10/13/2025 by MarketBeat.com Staff
